30096-07-2

Basic information

• Product Name: Benzeneacetic acid, a-methyl-2-nitro-, methyl ester
• CAS NO: 30096-07-2
• Molecular Formula: C10H11NO4
• Molecular Weight: 209.202
• Mol File: 30096-07-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Benzeneacetic acid, a-methyl-2-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, a-methyl-2-nitro-, methyl ester(30096-07-2)
• EPA Substance Registry System: Benzeneacetic acid, a-methyl-2-nitro-, methyl ester(30096-07-2)

Safety Data

• Hazardous Substances Data: 30096-07-2(Hazardous Substances Data)

Upstream product

• 860786-10-3 dimethyl 2-methyl-2-(2-nitrophenyl)malonate 
• 26465-37-2 dimethyl 2-(2-nitrophenyl)malonate 
• 1493-27-2 ortho-nitrofluorobenzene 
• 3740-52-1 2-(2-nitrophenyl)acetic acid 
• 30095-98-8 methyl (2-nitrophenyl)acetate 
• 74-88-4 methyl iodide 
• 72658-09-4 (E)-(1-methoxyprop-1-enyloxy)trimethylsilane 
• 98-95-3 nitrobenzene 

Downstream Products

• 1616854-57-9 tert-butyl 4-(2-(1-methoxy-1-oxopropan-2-yl)phenylamino)piperidine-1-carboxylate 
• 1616851-89-8 2-(1-(1-(3-(2-chloro-5-methoxyphenoxy)-4-methylpentyl)piperidin-4-yl)-3-methyl-2-oxoindolin-3-yl)-N-methylacetamide 
• 1616851-91-2 2-(1-(1-(3-(3-methoxyphenoxy)-4-methylpentyl)piperidin-4-yl)-3-methyl-2-oxoindolin-3-yl)-N-methylacetamide 
• 1616854-62-6 methyl 2-(1-(1-benzylpiperidin-4-yl)-3-methyl-2-oxoindolin-3-yl)acetate 
• 1616851-48-9 2-(1-(1-benzylpiperidin-4-yl)-3-methyl-2-oxoindolin-3-yl)-N-methylacetamide 
• 1616854-64-8 2-(1-(1-benzylpiperidin-4-yl)-3-methyl-2-oxoindolin-3-yl)-N-methylacetamide 
• 1616851-50-3 2-(1-(1-cyclohexylpiperidin-4-yl)-3-methyl-2-oxoindolin-3-yl)-N-methylacetamide 
• 78266-67-8 2-(o-nitrophenyl)propionaldehyde 
• 1452823-85-6 1-(1-(cyclohex-1-en-1-yl)ethyl)-2-nitrobenzene 
• 1316859-99-0 potassium 2-(2-nitrophenyl)propanoate 
• 1316859-87-6 1,3-dimethoxy-5-(1-(2-nitrophenyl)ethyl)benzene 
• 1316859-86-5 1-(1-(4-fluorophenyl)ethyl)-2-nitrobenzene 
• 1316859-85-4 1-nitro-2-(1-(4-(trifluoromethyl)phenyl)ethyl)benzene 

Relevant articles and documents

Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure

Herein we report our efforts of developing reversible selective hMAO-B inhibitors based on isatin, a fragment in an X-ray crystal structure. Five different scaffolds were designed and many compounds were synthesized. Among them, compound A3 demonstrated very high potency and isoform selectivity against hMAO-B, 11 and 13 times more potent (IC50 = 3 nM) and 23.64 and 6.8 times more selective than the marked drugs, selegiline and safinamide. However, the endeavors to modify the polar 3-one group of isatin, that is in a hydrophobic environment in the binding site of hMAO-B, to small nonpolar hydrophobic groups did not bring about improved hMAO-B inhibitors, which may challenge our understanding of molecular interactions and molecular recognition in biological systems.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heterocyclyl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES

This application relates to compounds of the general Formula I and salts thereof, wherein X, R1A, R1B, R2, R3, R4, and R5 are as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.